McKesson Co. (NYSE:MCK) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 5,109,995 shares, a growth of 54.5% from the February 28th total of 3,307,858 shares. Based on an average trading volume of 1,746,868 shares, the short-interest ratio is presently 2.9 days. Approximately 2.7% of the shares of the stock are sold short.
A number of brokerages have recently commented on MCK. Zacks Investment Research upgraded McKesson from a “sell” rating to a “hold” rating in a research report on Wednesday, January 9th. ValuEngine upgraded McKesson from a “strong sell” rating to a “sell” rating in a research report on Monday, February 4th. Wolfe Research assumed coverage on McKesson in a report on Tuesday, April 2nd. They issued an “outperform” rating for the company. Barclays restated a “hold” rating and issued a $124.00 target price on shares of McKesson in a report on Sunday, January 6th. Finally, Deutsche Bank upgraded McKesson from a “sell” rating to a “hold” rating and set a $175.00 target price for the company in a report on Friday, January 25th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the stock. McKesson presently has a consensus rating of “Hold” and a consensus price target of $134.90.
Shares of NYSE:MCK traded up $2.37 during midday trading on Friday, hitting $117.58. 1,450,080 shares of the stock were exchanged, compared to its average volume of 1,514,250. The company has a current ratio of 1.02, a quick ratio of 0.57 and a debt-to-equity ratio of 0.81. McKesson has a 52-week low of $106.11 and a 52-week high of $160.84. The firm has a market cap of $22.12 billion, a price-to-earnings ratio of 9.32, a P/E/G ratio of 1.17 and a beta of 1.24.
The firm also recently announced a quarterly dividend, which will be paid on Monday, July 1st. Shareholders of record on Monday, June 3rd will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 1.33%. The ex-dividend date is Friday, May 31st. McKesson’s payout ratio is 12.36%.
Institutional investors have recently bought and sold shares of the business. Proficio Capital Partners LLC lifted its stake in McKesson by 161.2% during the fourth quarter. Proficio Capital Partners LLC now owns 222 shares of the company’s stock worth $25,000 after purchasing an additional 137 shares during the period. Bedel Financial Consulting Inc. raised its stake in shares of McKesson by 165.2% in the fourth quarter. Bedel Financial Consulting Inc. now owns 236 shares of the company’s stock valued at $26,000 after acquiring an additional 147 shares during the last quarter. Smart Portfolios LLC bought a new position in shares of McKesson in the first quarter valued at approximately $35,000. Investors Research Corp bought a new position in shares of McKesson in the first quarter valued at approximately $36,000. Finally, Dubuque Bank & Trust Co. raised its stake in shares of McKesson by 106.7% in the first quarter. Dubuque Bank & Trust Co. now owns 341 shares of the company’s stock valued at $40,000 after acquiring an additional 176 shares during the last quarter. 86.49% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Short Interest in McKesson Co. (MCK) Increases By 54.5%” was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/26/mckesson-co-mck-short-interest-up-54-5-in-march.html.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Further Reading: What does RSI mean?
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.